Keros Therapeutics, Inc. Summary
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. They are also developing KER-047, a small molecule product candidate for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension. Founded in 2015, the company is based in Lexington, Massachusetts.
Symbol
KROS
General Information
Company Name
Keros Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Stock Multiplier
0.57X
P/E Ratio
0.7X
Assets
Cash and Cash Equivalents
720.54 Million 

Total Current Assets
759.51 Million 

Total Non-current Assets
25.05 Million 

Net Accounts Receivable
17.29 Million 

Property, Plant, and Equipment
N/A 

Total Assets
784.56 Million 

Net Property, Plant, and Equipment
4.47 Million 

Liabilities
Total Liabilities
55.69 Million 

Total Current Liabilities
39.38 Million 

Total Non-current Liabilities
16.31 Million 

Accounts Payable
6.64 Million
Share Information
Shares Issued
40.56 Million 

Basic Shares Outstanding
40.56 Million 

Shares Authorized
200 Million
Shareholders' Equity
Retained Earnings
-420.33 Million 

Total Shareholders' Equity
728.87 Million 

Income
Gross Revenue
211.19 Million 

Net Income
148.45 Million 

Basic Earnings per Share
3.66 

Diluted Earnings per Share
3.62 

Operating Income
152.04 Million 

Expenses
Research and Development
48.71 Million 

Operating Expenses
59.21 Million 

Stock Info
Current Price
$14.51
Market Cap
$588.56M
Monthly Low
$13.34
Yearly Low
$9.55
Monthly High
$14.57
Yearly High
$700
Monthly Avg
$14.04
Yearly Avg
$29.49
Monthly Volatility
Low
Yearly Volatility
High
Recent Keros Therapeutics, Inc. News
07/06/2025
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Brokerages
06/11/2025
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
06/10/2025
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
06/06/2025
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
05/30/2025
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.9% - Here's What Happened
05/29/2025
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
05/29/2025
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
05/20/2025
Tema Etfs LLC Purchases Shares of 35,663 Keros Therapeutics, Inc. (NASDAQ:KROS)
05/15/2025
Occudo Quantitative Strategies LP Invests $1.64 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)
05/10/2025
What is Leerink Partnrs' Estimate for KROS FY2025 Earnings?
Keros Therapeutics, Inc. Stock vs Fundamentals
Recommendation
Hold
Keros Therapeutics, Inc. Stock Forecast
category
sentiment
volatility
growth
forecast
KROS
+2%
Cohorts
+1.3%
Industry
+2.2%
Biotechnology
Industry Forecast
Data as of: 07/27/2025
Outperformers
America Great Health
+15%
FibroGen, Inc.
+15%
Replimune Group, Inc.
+13%
Underperformers
Nuvation Bio Inc.
-4%
Atara Biotherapeutics, Inc.
-2%
Aurinia Pharmaceuticals Inc.
-2%